Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
Recruiting now
Conditions studied: Rectal Cancer
In brief
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy. The main question it aims to answer is: • Does amide proton transfer-weighted imaging predict the cancer response before surgery? Participants will underwent amide proton transfer-weighted imaging as part of their regular MRI examination.
Key facts
- Study ID
- NCT06719414
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
- People needed
- 320
- Starts
- 2024-10-22
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-01-27
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma
- Received neoadjuvant therapy before surgery
- Complete radical resection of rectal cancer and postoperative pathological examination
- Informed consent and signed the informed consent form
You may not qualify if…
- Poor image quality, such as severe artifacts
- Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment
- The interval between preoperative MRI and surgery was more than 2 weeks
- Prior treatment for rectal cancer
- History of other malignant tumors
- Patients who cannot undergo MRI examination due to contraindications or relative contraindications
- Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
Where it is running
- Sixth Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
- Xinyi People's Hospital — Maoming, Guangdong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.